Apimeds Pharmaceuticals US (APUS) Return on Assets (2025)

Apimeds Pharmaceuticals US (APUS) reported Return on Assets of 0.0% for Q4 2025, up 73.36% quarter-over-quarter from 0.01% in Q3 2025.

Apimeds Pharmaceuticals US (APUS) Return on Assets (2025) Analysis & Trends

Apimeds Pharmaceuticals US has reported Return on Assets for 1 years, with the latest figure at 0.0% in Q4 2025.

For the quarter ending Q4 2025, Return on Assets changed N/A year-over-year to 0.0%; the trailing twelve-month figure through Dec 2025 stood at 0.0% (changed N/A YoY), and the FY2025 full-year result was 0.0%, up 6.0% from the prior year.
Return on Assets for Q4 2025 stood at 0.0%, up from 0.01% in the prior quarter.
The five-year high for Return on Assets was 0.0% in Q4 2025, with the low at 0.11% in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROA (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn	0.00%
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn	0.00%
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn	0.00%
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn	0.00%
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn	0.00%
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn	0.00%
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn	0.00%
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn	0.00%
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn	0.00%
10	Apimeds Pharmaceuticals US	13.93 Mn	10.29 Mn	-	0.00%

Download Data